A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain
PHASE2CompletedINTERVENTIONAL
Enrollment
266
Participants
Timeline
Start Date
October 31, 2013
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
Conditions
Osteoarthritis
Interventions
DRUG
AKR 202
DRUG
Placebo
Trial Locations (1)
Unknown
Clinical study center, Vienna
All Listed Sponsors
lead
Akron Molecules AG
INDUSTRY
NCT02003118 - A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain | Biotech Hunter | Biotech Hunter